Miria Chitukuta, a member of the HPTN 084 and HPTN 084-01 study protocol teams, is a social and behavioral scientist at the University of Zimbabwe Clinical Trials Research Centre (UZCTRC) in Harare, Zimbabwe. She has extensive experience coordinating and implementing qualitative research programs and has supported several Phase III HIV prevention clinical trials focusing on adolescent girls and women. 

Dr. Brenda Gati Mirembe, HPTN 111 co-chair, is a senior Investigator for MU-JHU CARE LTD in Kampala, Uganda. She has more than 14 years of experience in primary HIV prevention among adolescent girls and women. Dr. Mirembe has supported several studies, including the safety of long-acting cabotegravir injection among adolescent girls (HPTN 084-01).

Brian Minalga is the deputy director of the Office of HIV/AIDS Network Coordination (HANC) based at the Fred Hutchinson Cancer Center in Seattle. HANC supports all aspects of clinical trial operations across the ACTG, HPTN, HVTN, and IMPAACT. Brian also directs the HANC Legacy Project, focusing on including underrepresented populations in HIV clinical trials.

Juliane Etima, HPTN 084 and HPTN 111 study team member, is director of psychosocial support services at the MU-JHU Research Collaboration in Kampala, Uganda. She has extensive experience in the provision of social, emotional, and educational support and innovations for empowerment and equity for children, youth, women, and their families affected by HIV/AIDS.